Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
about
Clinical Implications of Antiviral Resistance in InfluenzaAssays for monitoring susceptibility of influenza viruses to neuraminidase inhibitorsPeramivir injection in the treatment of acute influenza: a review of the literatureReverse Genetics Approaches for the Development of Influenza VaccinesUnique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.Drug resistance in influenza A virus: the epidemiology and management.Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II studyNew small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusionCombination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.Detection and Characterization of Clade 1 Reassortant H5N1 Viruses Isolated from Human Cases in Vietnam during 2013Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patientsMonitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010.Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysisNeuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.Peramivir for the treatment of influenza.Recent progress and challenges in the discovery of new neuraminidase inhibitors.Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations.Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in SwedenCharacteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013-2014 influenza season in Mainland China.Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.Microevolution of highly pathogenic avian influenza A(H5N1) viruses isolated from humans, Egypt, 2007-2011.Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.Influenza neuraminidase: a druggable target for natural products.Improving influenza virus detection.Detection and management of antiviral resistance for influenza viruses.Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteersNeuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors
P2860
Q26782746-7557B67D-852B-4AD3-A0F6-B2F33FDEEFF3Q27013442-946CAFE9-E6EE-4B41-B8EB-28D736E983E0Q28068310-24F883CB-9E42-4527-97AD-9E1D601102CEQ28076140-47F87857-AC88-4C8F-8F9F-5BE800941D13Q30202859-9E097268-2DC7-426A-A040-6ADF675D41DCQ30218773-285CF173-5806-47E1-8314-D817E8F95C87Q30234600-FE60DDE1-846D-4067-91DE-AC9E82BC2350Q30353217-2E1F4174-168C-465E-8945-84386A0E2176Q30355297-129F5623-ABBF-4AEB-B214-98B0C5EA7CB7Q30364319-C591DA3C-D7A3-4A01-AB99-B9C72BDEB857Q30377552-6DE2A003-2A27-4FFE-A993-671744946BDAQ30396031-C8BBAB49-E978-4EA9-BDEF-D996566B57DAQ30397216-BBEBE3F2-9CD8-4BA6-87C0-702E38F1A8A6Q30400621-ED2825E9-1ACB-4F13-B0B2-7BEC73229DC9Q30404485-91EB73CB-6CC1-4CAE-ADD2-7AAC1EB68166Q30408105-DAFB8EEF-5B37-4424-B272-5EC481377C5DQ30412554-74F170FC-701D-48AA-BD83-07714D4F9B19Q30413154-D385A776-C481-420E-9AEB-ABDFC913C7F2Q30426630-F330A764-AF36-4F41-9242-4EC6A7FC2580Q30429450-E7454119-9B2C-489F-A1F4-EC72B7F87BD8Q34292717-3457F487-A7FE-4E37-8022-B2110AEAFE69Q35099847-EBB0C1C7-1E31-40D7-A152-814C1B49FB83Q35794372-97FB73D6-0B58-4808-8A4A-37DFA9802279Q35806412-70CC94DB-AD3E-41D9-A1A4-157790361F10Q36301052-35D6EB91-74B5-49A5-9419-E954907E0A73Q36584392-CFEB9BBE-CE85-4956-8344-5F81F46FEE06Q36785817-D64D8E6B-0546-43CF-B185-EC7B7C976CB0Q37263328-FD52479B-8EE5-4A53-86D4-10955935B5CAQ37949284-9C074847-1707-491C-8D08-FA8863E8551FQ38088381-615082CA-60DB-4FF0-91E6-80F68D281BA4Q38161553-C0337418-0957-4293-8E4E-C6546FF7D25EQ38804059-A343B215-0206-4D74-903D-B05D4335300EQ42110576-BD732135-9C82-4571-B589-3A7899E7404BQ45947329-BB188EB3-4481-48AC-8DA5-468A17569429Q52602393-A845DB5E-9930-4901-B6CE-5BE434509478Q57010547-9E3FD549-E272-4D12-8F82-172AE14F34B0
P2860
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assessment of pandemic and sea ...... me activity inhibition assays.
@ast
Assessment of pandemic and sea ...... me activity inhibition assays.
@en
type
label
Assessment of pandemic and sea ...... me activity inhibition assays.
@ast
Assessment of pandemic and sea ...... me activity inhibition assays.
@en
prefLabel
Assessment of pandemic and sea ...... me activity inhibition assays.
@ast
Assessment of pandemic and sea ...... me activity inhibition assays.
@en
P2093
P2860
P356
P1476
Assessment of pandemic and sea ...... me activity inhibition assays.
@en
P2093
Alexander I Klimov
Ha T Nguyen
Larisa V Gubareva
Tiffany G Sheu
Vasiliy P Mishin
P2860
P304
P356
10.1128/AAC.00581-10
P407
P577
2010-06-28T00:00:00Z